Seeking Alpha
17 Nov 2026, 20:42 UTC · 5h ago
Olema Oncology, Inc. (OLMA) Olema Pharmaceuticals, Inc. Presents at UBS Global Biopharma Conference 2026 Transcript
Impact · against what's priced in
The announcement of Phase III OPERA-01 data for palazestrant in early 2027 is a known catalyst and does not move the needle on current valuation. While the company is praised for execution, there is no new clinical data or timeline shift provided to change existing price expectations.
- OLMA+0.00
No priced-in read yet





